Visit Capella to learn more about the scientific and clinical progress we and our collaborators are making to advance the field of RNAi.
Regulus Therapeutics Inc. is a biopharmaceutical company formed (with Isis Pharmaceuticals) to discover, develop and commercialize miRNA therapeutics.
Business development is integral to our strategy of building a leading biopharmaceutical company. We forge creative partnerships with other innovative companies that advance our business and the field of RNAi.
Since our inception in 2002, we have formed more than 45 different relationships with major pharmaceutical companies, top-tier biotechnology companies, the federal government, and medical research foundations. These partnerships have generated more than $750 million in realized funding for us to date, forming the foundation of our extraordinarily strong balance sheet and making it possible for us to invest in and advance our own platform and pipeline while minimizing the need for dilutive capital. Our partnerships also provide valuable product rights, technology, development and commercialization expertise, and the potential for future funding from milestone and royalty payments. By enabling our partners to participate in the field of RNAi, we increase the number of therapeutics that could be created to address important patient medical needs.
Business development at Alnylam is made possible by our unparalleled intellectual property (IP) position, our leadership in translating the science of RNAi into a robust product platform and pipeline, and most importantly the remarkable talent and commitment of everyone at the company.
Our business development activities include: